Clinical trial • Phase IV|Phase II • Dermatology
GLUCOSE for Severe burns
Phase IV|Phase II trial of GLUCOSE for Severe burns. None/Not specified-controlled. 15 participants.
Overview
- Trial Therapeutic Area
- Dermatology
- Trial Disease
- Severe burns
- Trial Stage
- Phase IV|Phase II
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 13-05-2024
- First CTIS Authorization Date
- 03-09-2024
Trial design
None/Not specified-controlled Phase IV|Phase II trial across 1 site in France.
- Comparator
- None/Not specified
- Target Sample Size
- 15
- Trial Duration For Participant
- 4
Eligibility
Recruits 15 Vulnerable population is selected. Written consent is required from the patient; if the patient is unable to sign/express consent, consent may be obtained from the trusted person, family or relatives. Emergency inclusion is permitted if the patient is unable to express consent and neither the trusted person nor any family/relatives are present. Patients under guardianship, curatorship or safeguard of justice are excluded..
- Pregnancy Exclusion
- Pregnant, parturient or breast-feeding women
- Vulnerable Population
- Vulnerable population is selected. Written consent is required from the patient; if the patient is unable to sign/express consent, consent may be obtained from the trusted person, family or relatives. Emergency inclusion is permitted if the patient is unable to express consent and neither the trusted person nor any family/relatives are present. Patients under guardianship, curatorship or safeguard of justice are excluded.
Inclusion criteria
- {"criterion_text":"- Patients over 18 years of age"}
- {"criterion_text":"- Patients hospitalized with burns of at least 30% of body surface area o By a thermal mechanism o At the CHR Metz-Thionville burn center o managed within the 8 hours post-burn"}
- {"criterion_text":"- Patient affiliated to a social security scheme"}
- {"criterion_text":"- Written consent obtained from the patient (or from the trusted person, family or relatives if the patient is unable to sign/express consent) or emergency inclusion if the patient is unable to express consent and neither the trusted support person nor any member of the family or relatives is present at the time of inclusion"}
Exclusion criteria
- {"criterion_text":"- Diabetic patients on insulin"}
- {"criterion_text":"- Cognitive impairment or language barrier"}
- {"criterion_text":"- Patient with a CONTRAINDICATION to GLUCOSE 30% PROAMP, solution for injection"}
- {"criterion_text":"- Patients with pre-hospital cardiac arrest"}
- {"criterion_text":"- Patient with extra corporeal circulation : Extra Corporeal Membranous Oxygenation (ECMO) or Extra Corporeal Life Support (ECLS) or CRRT (Continuous Renal Replacement Therapy)"}
- {"criterion_text":"- Patient without central venous line or arterial catheter"}
- {"criterion_text":"- Patient moribund or immediately subject to therapeutic limitation"}
- {"criterion_text":"- Impossibility of trans-pulmonary thermodilution monitoring (vascular access difficulties)"}
- {"criterion_text":"- Pregnant, parturient or breast-feeding women"}
- {"criterion_text":"- Patient under guardianship, curatorship or safeguard of justice"}
Endpoints
Primary endpoints
- {"endpoint_text":"- The IDVG is calculated according to the method described by Hitota et al. A reference blood glucose level is measured on an arterial blood sample (arterial catheter) by a blood glucose meter. A bolus of 5 g of glucose is injected into a central venous line over 30 seconds. A second blood glucose level is measured 3 minutes after the end of the injection. The difference between the two blood glucose levels is recorded as d[glu] in mg/dl. IDVG = 24.4 x e(-0.0298 * d[glu]) + 2.7 in liters","definition_or_measurement_approach":"IDVG calculated per Hitota et al.: measure arterial reference blood glucose, inject 5 g glucose bolus via central venous line over 30 seconds, measure second arterial glucose 3 minutes after injection, record difference d[glu] (mg/dl); compute IDVG = 24.4 x e(-0.0298 * d[glu]) + 2.7 (liters)."}
Secondary endpoints
- {"endpoint_text":"- ITBV (intra-thoracic blood volume) and EVLW (extra-vascular lung water) measured at the same time as IDVG, using the PiCCO device and trans-lung dilution of a thermal indicator (cold saline).","definition_or_measurement_approach":"Measured concurrently with IDVG using the PiCCO device via trans-pulmonary thermodilution (thermal indicator: cold saline)."}
- {"endpoint_text":"- Body surface area assessed on admission (Wallace method)","definition_or_measurement_approach":"Assessment of body surface area on admission using the Wallace method."}
- {"endpoint_text":"- Water intake and input/output balance (water intake minus diuresis)","definition_or_measurement_approach":"Calculation of water balance as water intake minus diuresis (input/output recording)."}
- {"endpoint_text":"- In-hospital mortality","definition_or_measurement_approach":"Recording of mortality occurring during hospital stay."}
- {"endpoint_text":"- Arterial blood glucose levels will be measured in g/L just before and 3 minutes after the end of the glucose bolus injection, using a glucometer.","definition_or_measurement_approach":"Arterial blood glucose measured in g/L with a glucometer immediately before and 3 minutes after glucose bolus injection."}
Recruitment
- Planned Sample Size
- 15
- Recruitment Window Months
- 28
- Consent Approach
- Written consent obtained from the patient; if the patient is unable to sign/express consent, consent may be obtained from the trusted person, family or relatives. Emergency inclusion allowed if patient unable to express consent and neither the trusted support person nor any family/relatives is present at time of inclusion.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 15
France
- Earliest CTIS Part Ii Submission Date
- 09-07-2024
- Latest Decision Or Authorization Date
- 03-09-2024
- Processing Time Days
- 56
- Number Of Sites
- 1
- Number Of Participants
- 15
Sites
- Site Name
- Centre Hospital Region Metz Thionville
- Department Name
- Centre de Traitement des Grands-Brûlés
- Principal Investigator Name
- Serge LE TACON
- Principal Investigator Email
- serge.le-tacon@chr-metz-thionville.fr
- Contact Person Name
- Serge LE TACON
- Contact Person Email
- serge.le-tacon@chr-metz-thionville.fr
- Number Of Participants
- 15
Sponsor
Primary sponsor
- Full Name
- Centre Hospital Region Metz Thionville
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- GLUCOSE 30 % PROAMP, solution injectable
- Active Substance
- GLUCOSE
- Modality
- Small molecule
- Routes Of Administration
- IV INJECTION, IV INFUSION
- Route
- IV (central venous line)
- Authorisation Status
- Marketing authorisation number: 34009 371 747 7 0 (France)
- Starting Dose
- 5 g bolus
- Dose Levels
- 5 g (single bolus for IDVG measurement)
- Frequency
- Single bolus at measurement times (one-time injection for IDVG measurement)
- Maximum Dose
- 300 mg/kg/h
Related trials
Other published trials that may interest you.